2,46 Mb - GuÃaSalud
2,46 Mb - GuÃaSalud
2,46 Mb - GuÃaSalud
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
IGT<br />
INSIGHT Trial<br />
IV<br />
LDL<br />
LH<br />
LIFE Trial<br />
MET<br />
MF<br />
n<br />
NHS<br />
NICE<br />
NNH<br />
NNT<br />
NPV<br />
ODA<br />
OGTT<br />
OR<br />
PAD<br />
PDE<br />
PPV<br />
RCT<br />
RR<br />
SMBG<br />
SBP<br />
SDU<br />
SIGN<br />
SR<br />
SSRI<br />
SU<br />
TG<br />
VLDL<br />
Impaired glucose tolerance<br />
Intervention as a Goal in Hypertension Treatment<br />
Intravenous<br />
Low-density lipoprotein<br />
Likelihood ratio<br />
Cardiovascular morbidity and mortality in the Losartan Intervention for<br />
Endpoint reduction in hypertension study<br />
Metabolic Equivalent T<br />
Monofilament<br />
Number of patients<br />
National Health System<br />
National Institute for Clinical Excellence<br />
Number needed to harm<br />
Number needed to treat<br />
Negative predictive value<br />
Oral anti-diabetic agent<br />
Oral glucose tolerance test<br />
Odds Ratio<br />
Peripheral arterial disease<br />
Phosphodiesterase<br />
Positive predictive value<br />
Randomised clinical trial<br />
Relative risk<br />
Self-monitoring of blood glucose<br />
Systolic blood pressure<br />
Standard drinking unit which is equivalent to 10 g of pure alcohol<br />
Scottish Intercollegiate Guidelines Network<br />
Systematic Review<br />
Selective serotonin reuptake inhibitor<br />
Sulfonylurea<br />
Triglycerides<br />
Very low-density lipoprotein<br />
CLINICAL PRACTICE GUIDELINE ON TYPE 2 DIABETES 159
Change language